NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research

        • Research Overview
        • Clinical Research Facility
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient & Public Involvement
    • Getting involved with research
    • View and register for involvement opportunities
    • Patient & Public Groups
    • Patient and Public Involvement Advisory Group
    • Diversity in Research Group
    • Oxford Blood Group
    • Case Studies
    • PPIE Strategy
    • PPIE News
    • PPI Researcher Guidance
    • Researchers: Post a PPIE opportunity
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > COVID-19 > Study finds no increased risk of rare neurological events after COVID vaccination

Study finds no increased risk of rare neurological events after COVID vaccination

17 March 2022 · Listed under COVID-19, Musculoskeletal, Preventive Neurology

A study of more than eight million people has found no increased risk of rare neurological events after COVID -19 vaccination.

Photo: National Cancer Institute via Unsplash

However, the researchers did find a higher risk of Bell’s palsy (facial weakness), encephalomyelitis (inflammation of the brain and spinal cord) and Guillain-Barré syndrome (a nerve condition) after COVID-19 infection.

The study, which was supported by the NIHR Oxford Biomedical Research Centre, was published by The BMJ.

Following reports that some people developed Guillain-Barré syndrome after receiving the Oxford-AstraZeneca or Pfizer-BioNTech COVID vaccines, the European Medicines Agency listed Guillain-Barré syndrome as a rare side effect of these vaccines.

However, so far, the results from research into the risk of Guillain-Barré syndrome – and other immune-mediated neurological disorders – after COVID-19 vaccination have been mixed.

To address this, researchers, led by Professor Daniel Prieto-Alhambra of the University of Oxford’s Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, set out to study the association between COVID-19 vaccines, infection with SARS-CoV-2 (the virus responsible for COVID-19), and risk of immune mediated neurological events.

Their findings are based on data from two large electronic primary care health record databases in the UK and Spain. 

They included 8.3 million individuals who received at least one dose of a COVID-19 vaccine (Oxford-AstraZeneca, Pfizer-BioNTech, Moderna or Johnson & Johnson), 735,870 unvaccinated individuals with a positive COVID-19 test result, and 14.3 million individuals from the general population.

The team were interested in four immune mediated neurological disorders: Bell’s palsy (facial weakness), encephalomyelitis (inflammation of the brain and spinal cord), Guillain-Barré syndrome (a nerve condition), and transverse myelitis (inflammation of the spinal cord).

Rates of these disorders were estimated in the 21 days after the first vaccine dose, 90 days after a positive test result, and between 2017 and 2019 for background rates in the general population group.

Overall, the researchers found that post-vaccine rates were consistent with expected (background) rates for Bell’s palsy, encephalomyelitis and Guillain-Barré syndrome. Rates of transverse myelitis were rare (less than five events in all vaccinated groups) so could not be analysed.

Prof Daniel Prieto-Alhambra, who led the research

Rates of Bell’s palsy, encephalomyelitis and Guillain-Barré syndrome were, however, higher than expected after COVID-19 infection.

This is an observational study so cannot establish cause, and the researchers cannot rule out the possibility that unknown differences between groups or misclassification of disorders may have affected their results.

But they point out that several other studies have also reported increased risks of immune mediated neurological events after COVID-19 infection, suggesting their results are robust. 

As such, they say: “We found no safety signal for any of the studied immune mediated neurological events after vaccination against COVID-19. Infection with SARS-CoV-2 was, however, associated with an increased risk of Bell’s palsy, encephalomyelitis, and Guillain-Barré syndrome.”

Further evidence is needed to understand the long-term adverse events of vaccination and SARS-CoV-2 infection, while larger cohorts are also needed to study the effect of vaccination on different age groups, particularly among younger populations, they add.

In a linked editorial in the BMJ, experts say it is important to note that all risks – even those observed after SARS-CoV-2 infection – are small in absolute terms for the single individual. However, they note that even small absolute risks “can lead to a substantial burden on the healthcare system in the context of mass vaccination and widespread infection.”

Researchers and clinicians have a responsibility to discuss these findings with affected patients and their families, they say, while at the same time acknowledging the inherent uncertainties in making patient-level inferences from population level studies.

One approach would be to explain that although neurological conditions do occasionally occur shortly after COVID-19 vaccination, good evidence from very large studies shows that these conditions are no more common among vaccinated people than among unvaccinated people. 

“We may never be able to tell exactly what caused an individual to develop a neurological condition, but COVID -19 vaccination is a highly unlikely reason for most,” they conclude.

← First UK pilot study of newborn screening for spinal muscular atrophy launched
New drug no more effective than current treatments for post-operative knee pain →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2023 NIHR Oxford Biomedical Research Centre